Methods and compositions for the treatment and prevention of lung disease

Inactive Publication Date: 2006-06-01
MASSARO DONALD +2
View PDF14 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0019] By “therapeutically effective amount” is meant that the amount of the RAR-specific therapeutic agent is sufficient, either as the result of a single dose, or as the result of multiple doses over the term of therapy, to decrease the rate of alveolar destruction in an emphysemic mammal, or to promote the growth of alveolar septa in said mammal.

Problems solved by technology

Lack of adequate gas exchange would lead to disability, which could progress to death.
Diseases that result in fewer alveoli therefore are quite serious, and are common causes of inadequate oxygenation and resultant disability and death.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for the treatment and prevention of lung disease
  • Methods and compositions for the treatment and prevention of lung disease

Examples

Experimental program
Comparison scheme
Effect test

example 1

Involvement of RAR Receptors in Alveolus Formation

[0037] In most mammals new alveoli are formed postnatally; thus the lung of many newborn mammals is immature, and not merely a smaller version of the adult lung. For example, in humans alveolus formation can continue up to the age of 20.

[0038] The study of alveolus development in newborn mammals, in this case newborn rats, therefore provides an opportunity to study the effect of various agents on alveolus formation. The rate of increase in specific lung volume (expressed as cm3 / 100 g body weight) in rats is greatest within the first 10 days following birth, after which it increases at a less steep rate.

[0039] However, the lung's efficiency is determined not merely by the volume of air that can be contained in the lung, but by the alveolar surface area, which is a function of tissue growth within the lung. Burri et al., Anat. Rec. 178:711-730 (1973) and Burri, Anat. Rec. 180-77-98 (1974) performed extensive studies of the postnatal...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Surface areaaaaaaaaaaa
Login to view more

Abstract

Methods and compositions for the treatment of lung disease such as emphysema and / or bronchopulmonary dysplasia in a mammal. Also disclosed are methods and compositions promoting the formation of alveolar septa and increasing the gas-exchange surface area of a mammalian lung, and for the prevention and / or treatment of alveolar destruction.

Description

RELATED APPLICATION(S) [0001] This application is a continuation of U.S. application Ser. No. 10 / 305,049, filed Nov. 25, 2002, now U.S. Pat. No. 6,492,414, which is a continuation of U.S. application Ser. No. 09 / 549,226, filed Apr. 13, 2000, which claims the benefit of U.S. Provisional Application No. 60 / 129,216, filed Apr. 14, 1999. The entire teachings of the above application(s) are incorporated herein by reference.FIELD OF THE INVENTION [0002] This invention concerns the use of isotype-specific retinoic acid receptor (RAR) agonists for the inhibition of alveolar destruction and / or to promote the formation of alveoli in mammalian lung tissue deficient in adequate numbers of functional alveoli. BACKGROUND OF THE INVENTION [0003] Among aerobic animals, the lung functions to provide an interface for the exchange of gases between blood and the atmosphere. The agents of this exchange are numerous small sacs termed alveoli (in adult humans about 300,000,000 per lung) that provide a gas...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/203A61K31/07A61K31/00A61K31/381A61P11/00
CPCA61K31/00A61K31/07A61K31/203A61K31/381A61P11/00
Inventor MASSARO, DONALDMASSARO, GLORIA DECARLOCHANDRARATNA, ROSHANTHA A.
Owner MASSARO DONALD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products